Crossmark

Preclinical exploration of combined glucagon inhibition and liver-preferential insulin for treatment of diabetes using in vitro assays and rat and mouse models

Crossref DOI link: https://doi.org/10.1007/s00125-022-05828-w

Published Online: 2022-11-21

Published Print: 2023-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hvid, Henning https://orcid.org/0000-0002-3667-4141
Brand, Christian L.

Hummelshøj, Tina

Jensen, Sanne

Bouman, Stephan D.

Bowler, Andrew

Poulsen, Bjarne R.

Tiainen, Peter

Åkertröm, Thorbjörn

Demozay, Damien

Hoeg-Jensen, Thomas

Ingvorsen, Camilla

Pedersen, Thomas Å.

McGuire, Jim

Egebjerg, Thomas

Cappelen, Karen A.

Eliasen, Ina P.

Hansen, Bo F.

Hennen, Stephanie

Stidsen, Carsten E.

Olsen, Grith S.

Roed, Nikolaj K. https://orcid.org/0000-0002-7017-1716
License Information

Text and Data Mining valid from 2022-11-21

Version of Record valid from 2022-11-21
More Information

Article History

Received: 8 July 2022

Accepted: 22 September 2022

First Online: 21 November 2022

Document is current

Any future updates will be listed below